Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response and Oxidative Stress Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for POLDIP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | POLDIP2 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. |
View POLDIP2 Products |
| Gene Delivery | POLDIP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View POLDIP2 Products |
| Benchmark Ab | Anti-POLDIP2 Benchmark Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View POLDIP2 Products |
| Validator | POLDIP2 siRNA Set Target-specific knockdown verification in phenotype and functional assays. |
View POLDIP2 Products |
| Related Target A | PCNA (Proliferating Cell Nuclear Antigen) Direct binding partner of POLDIP2; critical for DNA replication fork progression and translesion synthesis (TLS). |
View PCNA Products |
| Related Target B | POLD3 (DNA Polymerase Delta Subunit 3) Interacts with POLDIP2 to mediate polymerase delta activity during DNA repair and replication. |
View POLD3 Products |
| Related Target C | NOX4 (NADPH Oxidase 4) POLDIP2 regulates NOX4-derived ROS production, making it a key node in vascular remodeling and oxidative stress. |
View NOX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (e.g., POLDIP2-PCNA or POLDIP2-NOX4) | High-purity recombinant proteins (>95% by SDS-PAGE) with precise sequence verification for reliable biophysical assays (SPR/BLI). |
| Physiological conformation in cell-based assays | Lentiviral vectors optimized for stable cell line generation, avoiding transient transfection artifacts in phenotypic screening. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA sets included for robust positive and negative controls. |
| False Positives in High-Throughput Screening | Endotoxin-controlled, high-purity recombinant proteins minimize non-specific binding and cell toxicity during screening. |
Live POLDIP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for POLDIP2 therapeutics is intensifying, with major players shifting focus from traditional targets to novel DNA Damage Response (DDR) and oxidative stress modulators. As first-generation oncology and cardiovascular therapies target replication stress and fibrotic pathways, the next wave of R&D is targeting protein-protein interactions (PPIs) involving POLDIP2. Disrupting POLDIP2's interaction with PCNA or NOX4 offers a highly selective approach to sensitizing cancer cells to chemotherapy or mitigating vascular remodeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (PPI disruptors) | Academic Institutes, Biotech Startups | Solid Tumors (Chemoresistance), Fibrosis | Protein-Protein Interaction assays (Requires high-purity POLDIP2 and PCNA/NOX4 proteins) |
| Gene Therapy / RNAi | Preclinical Stage Biopharma | Vascular Diseases, Pulmonary Arterial Hypertension | Target knockdown validation (Requires sequence-verified POLDIP2 siRNA and Lentivirus) |
| Targeted Protein Degraders (PROTACs) | DDR-focused Biotechs | BRCA-deficient Cancers, Refractory Tumors | Ubiquitination and degradation assays (Requires high-purity recombinant proteins and stable cell lines) |